| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Articles |
Lundberg Laboratory for Diabetes Research, Department of Medicine, Sahlgrenska University Hospital (J.W.E., P.L., C.W., U.S.), Goteborg; and the Department of Medicine, Norrland University Hospital (J.W.E.), Umea, Sweden
Address all correspondence and requests for reprints to: Dr. Jan Eriksson, Department of Medicine, Norrland University Hospital, S-901 85 Umea, Sweden.
The aim of the present study was to elucidate events in the plasma
membrane (PM) associated with the previously described effect of
insulin to rapidly enhance the number of cell surface insulin binding
sites in rat adipocytes. [125I]insulin was cross-linked
to cell surface insulin receptors of intact cells that had been
preincubated with or without insulin. Subsequently prepared PM
displayed a
3-fold increase in bound [125I]insulin
when cells had been pretreated with 6 nM insulin for 20 min
compared to membranes from control cells, and SDS-PAGE with
autoradiography showed that this occurred at the insulin receptor
-subunit. The magnitude of the effect was similar to that found for
insulin binding to intact cells that had been preincubated with
insulin. In contrast, the insulin binding capacity in the PM was not
affected by prior treatment of cells with insulin when assessed with
the addition of [125I]insulin directly to solubilized PM;
this suggests an unchanged total number of PM receptors. Thus, the
enhancement of cell surface insulin binding capacity produced by
insulin is not due to the translocation of receptors, but instead
appears to be confined to receptors already present in the PM. The
addition of phospholipase C (from Clostridium
perfringens), which cleaves PM phospholipids, mimicked the
effect of insulin to enhance cell surface binding in adipocytes, and
this suggests a pool of cryptic PM receptors. Both the nonmetabolizable
cAMP analog N6-monobutyryl cAMP
(N6-mbcAMP) and the serine/threonine
phosphatase inhibitor okadaic acid abolished the effect of concomitant
insulin treatment to increase binding capacity. In contrast, the
tyrosine phosphatase inhibitor vanadate increased insulin binding even
in the presence of okadaic acid or
N6-mbcAMP. The effect of
N6-mbcAMP to impair cell surface insulin
binding was also evident in the presence of a peptide derived from the
major histocompatibility complex type I that effectively impairs
receptor internalization, but the amount of PM receptors assessed by
immunoblot was unaltered.
Taken together, the data suggest that insulin exposure leads to the uncovering of cryptic receptors associated with the PM. It is also suggested that tyrosine phosphorylation promotes this process, whereas enhanced serine phosphorylation, e.g. produced by cAMP, impairs the functional insertion of the receptors, rendering them unable to bind insulin.
This article has been cited by other articles:
![]() |
L. Braiman, A. Alt, T. Kuroki, M. Ohba, A. Bak, T. Tennenbaum, and S. R. Sampson Insulin Induces Specific Interaction between Insulin Receptor and Protein Kinase C{{delta}} in Primary Cultured Skeletal Muscle Mol. Endocrinol., April 1, 2001; 15(4): 565 - 574. [Abstract] [Full Text] |
||||
![]() |
T. Amit, O. Bar-Am, F. Dastot, M. B. H. Youdim, S. Amselem, and Z.'e. Hochberg The Human Growth Hormone (GH) Receptor and Its Truncated Isoform: Sulfhydryl Group Inactivation in the Study of Receptor Internalization and GH-Binding Protein Generation Endocrinology, January 1, 1999; 140(1): 266 - 272. [Abstract] [Full Text] |
||||
![]() |
S. Yu, A. Castle, M. Chen, R. Lee, K. Takeda, and L. S. Weinstein Increased Insulin Sensitivity in Gsalpha Knockout Mice J. Biol. Chem., June 1, 2001; 276(23): 19994 - 19998. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |